-
Mashup Score: 7Are We Ready for Biosimilars in Multiple Sclerosis? Experts Discuss Lessons From Other Immune-Mediated Diseases - 8 month(s) ago
What is the clinical use of biosimilars and how to best communicate with patients to avoid the nocebo effect?
Source: www.medscape.orgCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
In a nationwide French study, researchers assessed whether vaccination was associated with the risk for hospitalization due to MS flare-ups.
Source: www.neurologyadvisor.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 5Racial and Ethnic Disparities in Multiple Sclerosis Prevalence - 8 month(s) ago
Background and Objectives The goal of this work was to determine whether the prevalence of multiple sclerosis (MS) varies by race and ethnicity. Methods We conducted a retrospective cohort study of >2.6 million adults from the multiethnic, community-dwelling members of Kaiser Permanente Southern California. The complete electronic health records of individuals with at least 1 ICD-9 code for MS between January 1, 2008 and December 31, 2010 were reviewed. MS prevalence and 95% CIs stratified by age, sex, and race and ethnicity among 2010 members were estimated with binomial regression. Age- and sex-standardized prevalence was estimated according to the 2010 US Census population. Results We identified 3,863 patients with MS. The average age of patients with prevalent MS was 51.7 years (SD 13.1 years), and 76.8% were women. The female preponderance was more pronounced among Black (81.2%) and Asian (83.6%) than White (76.3%) or Hispanic (74.5%) individuals with MS. Age- and sex-standardized
Source: n.neurology.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 6Neurology Video Journal Club: Multiple Sclerosis/Autoimmune Neurology | American Academy of Neurology Journals - 8 month(s) ago
Join us for this and future episodes to learn from experts as they discuss recent Neurology journal articles and hot topics in the field of neurology. Articles and discussants are selected by the editors of Neurology. Professor of Pediatrics, Director Pediatrics MS and Neuroinflammatory Disorders Program, Senior Scientist, University of Toronto The Hospital for Sick Children Research Daniela Castillo Villagr á n, MD Pediatric Neurologist, Clinical Fellow Pediatric MS & Neuroinflammatory Disorders
Source: www.neurology.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
Did you know what the inherent variability of all biologics and what degree of variation are acceptable by regulatory bodies?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 1
This cohort study examines whether different vaccines are associated with multiple sclerosis flare-ups requiring hospitalization.
Source: jamanetwork.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Neurology Today - 9 month(s) ago
Neurology Today reports on breaking news, issues, and trends in the practice and science of neurolog
Source: journals.lww.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 15Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis - 9 month(s) ago
Background and Objectives The optic nerve has been recommended as an additional region for demonstrating dissemination in space (DIS) in diagnostic criteria for multiple sclerosis (MS). The aim of this study was to investigate whether adding the optic nerve region as determined by optical coherence tomography (OCT) as part of the DIS criteria improves the 2017 diagnostic criteria. Methods From a prospective observational study, we included patients with a first demyelinating event who had complete information to assess DIS and a spectral domain OCT scan obtained within 180 days. Modified DIS criteria (DIS + OCT) were constructed by adding the optic nerve to the current DIS regions based on validated thresholds for OCT intereye differences. Time to second clinical attack was the primary endpoint. Results We analyzed 267 patients with MS (mean age 31.3 years [SD 8.1], 69% female) during a median observation period of 59 months (range: 13–98). Adding the optic nerve as a fifth region impr
Source: n.neurology.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0HOME - Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors - 9 month(s) ago
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the…
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis - 9 month(s) ago
Background and Objectives In multiple sclerosis (MS), accelerated aging of the immune system (immunosenescence) may be associated with disease onset or drive progression. DNA methylation (DNAm) is an epigenetic factor that varies among lymphocyte subtypes, and cell-specific DNAm is associated with MS. DNAm varies across the life span and can be used to accurately estimate biological age acceleration, which has been linked to a range of morbidities. The objective of this study was to test for cell-specific epigenetic age acceleration (EAA) in people with MS. Methods This was a case-control study of EAA using existing DNAm data from several independent previously published studies. Data were included if .idat files from Illumina 450K or EPIC arrays were available for both a case with MS and an age-matched and sex-matched control, from the same study. Multifactor statistical modeling was performed to assess the primary outcome of EAA. We explored the relationship of EAA and MS, including
Source: n.neurology.orgCategories: Latest Headlines, NeurologyTweet
📝 Are we ready for biosimilars in multiple sclerosis? Experts discuss lessons from other immune-mediated diseases. #CME #MS ➡️ Learn here: https://t.co/trm5SHUqTc https://t.co/XCkU10cacE